SUPRAX for ORAL SUSPENSION Rx
Generic Name and Formulations:
Cefixime 100mg/5mL, 200mg/5mL, 500mg/5mL; strawberry flavor; pwd for reconstitution.
Lupin Pharmaceuticals, Inc.
Indications for SUPRAX for ORAL SUSPENSION:
Susceptible infections, including otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis; uncomplicated UTIs and cervical or urethral gonorrhea.
400mg once daily or 200mg every 12 hrs. Gonorrhea: 400mg once. Infections due to Streptococcus pyogenes: treat for at least 10 days. Renal impairment: adjust dose; see full labeling.
<6 months: not established. Chew tabs: chew or crush before swallowing. <50kg and 6 months–12yrs: 8mg/kg once daily or 4mg/kg every 12 hrs. >50kg or >12yrs: use adult dose. Otitis media: treat with chew tabs or susp; do not substitute with tabs. Infections due to Streptococcus pyogenes: treat for at least 10 days.
Penicillin or other allergy. Renal impairment. History of GI disease. Chew tabs: phenylketonuria. Labor and delivery. Pregnancy (Cat.B). Nursing mothers.
May potentiate carbamazepine, anticoagulants (eg, warfarin) (monitor). May cause false (+) Clinitest, direct Coomb's, nitroprusside test for ketones. Potentiated by probenecid.
Diarrhea, nausea, loose stools, abdominal pain, dyspepsia, vomiting, hypersensitivity reactions, headache, dizziness, seizures, transient renal and hepatic effects; C. difficile-associated diarrhea.
Tabs—10, 50, 100; Chew tabs—10, 50; Susp 100mg/5mL—50mL, 75mL, 100mL; 200mg/5mL—25mL, 37.5mL, 50mL, 75mL, 100mL; 500mg/5mL—10mL, 20mL
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|